This review found that addition of bevacizumab to chemotherapeutic regimens significantly increased the risk of highgrade proteinuria in patients with cancer. The authors' conclusions reflect the evidence presented, but a limited search, potential for language bias and limitations in the data acknowledged should be considered.
Study selection
Randomised controlled trials in which combinations of chemotherapeutic treatment with bevacizumab were compared to chemotherapy without bevacizumab in patients with cancer were eligible for inclusion. Trials were required to report on the event or incidence of Grade 3-4 proteinuria and sample size. High grade proteinuria was the primary outcome of the review.
The malignancies of the patients in the trials were colorectal cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, renal cell carcinoma and malignant mesothelioma. Exclusion criteria varied widely between studies. Dosage of bevacizumab was either 2.5 or 5.0mg/kg per week. A range of concurrent chemotherapeutic agents was given in the studies. The patients were required to have adequate hepatic, renal and haematological function on entry to the studies and Eastern Cooperative Oncology group status for most patients was 0-1. Baseline renal function was not uniformly defined across the included studies and included normal, adequate or serum creatine less than 1.8 or 2.0mg/dL. Follow-up in the trials ranged from 6.7 to 27.6 months.
The authors did not state how many reviewers performed the study selection.
Assessment of study quality
Methodological quality was assessed in terms of concealment of randomisation, completeness of follow-up and use of objective outcome measurements.
The authors did not report how many reviewers performed the quality assessment.
Data extraction
Data were independently extracted by three reviewers to calculate relative risks (RR) and 95% confidence intervals (CI). The authors of the included trials were contacted where relevant data were unclear. Any discrepancies between the reviewers were resolved by consensus.
Methods of synthesis
Pooled relative risks and 95% CIs were calculated with both random-effects and fixed-effect models. Statistical heterogeneity was assessed using the Cochran Q-statistic and the I 2 test. When the Cochran Q-statistic was p<0.1, results of the random-effects model were reported and causes of heterogeneity were explored. The Begg test was used to evaluate publication bias. Subgroup analyses were conducted on the basis of bevacizumab dosage, malignancy type and use of platinum-based chemotherapy. The relationship between high grade proteinuria and clinical outcomes were evaluated.
Results of the review
Sixteen RCTs (n=12,268) were included in the review. Methodological quality of the trials was regarded as acceptable, with randomised allocation sequences generated in all trials, Incidence of high grade proteinuria for patients who received bevacizumab was 2.2% (95% CI 1.2 to 4.3%, I 2 =94%) in all 16 included trials. Risk of high-grade proteinuria was significantly higher for patients treated with bevacizumab (RR 4.79 (95% CI 2.71 to 8.46, Q=19.989, I 2 = 25%; 16 trials), as was risk of nephrotic syndrome (RR 7.78, 95% CI 1.80 to 33.62, Q=0.48, I 2 <0.001; four trials).
There were statistically significant increases in risk of high-grade proteinuria observed with both lower doses of bevacizumab compared to chemotherapy alone (2.5mg/kg/week, RR 2.62, 95%CI 1.61 to 4.28, I 2 <0.001; seven trials) and higher doses of bevacizumab compared to chemotherapy alone (5.0mg/kg/week, RR 8.56, 95% CI 4.09 to 17.92, I 2 =1.958; 10 trials). There appeared to be a dosage-dependent risk of high grade proteinuria, as the differences in risk between high-dose and low-dose bevacizumab was statistically significant (p=0.009).
Risk of high-grade proteinuria varied according to tumour type. There were statistically significant increases in risk of high-grade proteinuria with all malignancy types except malignant mesothelioma. Of the malignancy types with higher risks of proteinuria, the highest risk was observed for renal cell carcinoma (RR 48.76, 95% CI 9.73 to 244.40 ) and the lowest risk was for colorectal cancer (RR 2.52, 95% CI 1.54 to 4.15). Comparison between the relative risks associated with bevacizumab treatment in renal cell carcinoma and other malignancies showed a significantly higher risk with renal cell carcinoma (p=0.001).
There were no differences observed in risk of high-grade proteinuria associated with bevacizumab when it was compared with platinum-and non-platinum-based chemotherapeutic regimens.
For patients treated with bevacizumab, statistically significant benefits in progression-free survival and overall survival were observed for patients with non-small cell lung cancer and colorectal cancer and for progression-free survival in patients with breast cancer and renal cell carcinoma (data not reported).
The results of the Begg test indicated that there was no evidence of publication bias.
